Literature DB >> 8616713

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

S K Tripathy1, H B Black, E Goldwasser, J M Leiden.   

Abstract

The use of replication-defective adenoviruses (RDAd) for human gene therapy has been limited by host immune responses that result in transient recombinant gene expression in vivo. It remained unclear whether these immune responses were directed predominantly against viral proteins or, alternatively, against foreign transgene-encoded proteins. In this report, we have compared the stability of recombinant gene expression in adult immunocompetent mice following intramuscular (i.m.) injection with identical RDAd encoding self (murine) or foreign (human) erythropoietin. Our results demonstrate that immune responses direct against foreign transgene-encoded proteins are the major determinants of the stability of gene expression following i.m. injection of RDAd. Moreover, we demonstrate long-term recombinant gene expression in immunocompetent animals following a single i.m. injection of RDAd encoding a self protein. These findings are important for the design of future preclinical and clinical gene therapy trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616713     DOI: 10.1038/nm0596-545

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  136 in total

1.  Frequency and stability of chromosomal integration of adenovirus vectors.

Authors:  A Harui; S Suzuki; S Kochanek; K Mitani
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

5.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Restricting expression prolongs expression of foreign genes introduced into animals by retroviruses.

Authors:  V B Pinto; S Prasad; J Yewdell; J Bennink; S H Hughes
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Regulatory function of in vivo anergized CD4(+) T cells.

Authors:  K Jooss; B Gjata; O Danos; H von Boehmer; A Sarukhan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

8.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 9.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

10.  Detailed analysis of the CD8+ T-cell response following adenovirus vaccination.

Authors:  Teng Chih Yang; Kelley Dayball; Yong Hong Wan; Jonathan Bramson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.